70,185 Shares in Humana Inc. $HUM Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company purchased a new stake in shares of Humana Inc. (NYSE:HUMFree Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 70,185 shares of the insurance provider’s stock, valued at approximately $27,879,000. The Manufacturers Life Insurance Company owned about 0.06% of Humana at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HUM. Revolve Wealth Partners LLC bought a new position in shares of Humana during the fourth quarter valued at approximately $202,000. Woodline Partners LP boosted its holdings in Humana by 460.0% during the 1st quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock valued at $2,697,000 after acquiring an additional 8,372 shares during the period. Sivia Capital Partners LLC boosted its holdings in Humana by 53.7% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock valued at $316,000 after acquiring an additional 452 shares during the period. Cresset Asset Management LLC grew its position in Humana by 10.3% in the 2nd quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider’s stock valued at $581,000 after acquiring an additional 222 shares during the last quarter. Finally, WINTON GROUP Ltd grew its position in Humana by 58.5% in the 2nd quarter. WINTON GROUP Ltd now owns 2,381 shares of the insurance provider’s stock valued at $582,000 after acquiring an additional 879 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of HUM stock opened at $392.72 on Friday. Humana Inc. has a twelve month low of $163.11 and a twelve month high of $428.88. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. The stock has a fifty day simple moving average of $385.08 and a two-hundred day simple moving average of $287.78. The stock has a market capitalization of $47.16 billion, a price-to-earnings ratio of 37.15, a P/E/G ratio of 2.23 and a beta of 0.72.

Humana (NYSE:HUMGet Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, beating the consensus estimate of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The firm had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. During the same quarter last year, the firm posted $6.27 earnings per share. The business’s revenue for the quarter was up 26.2% on a year-over-year basis. On average, analysts predict that Humana Inc. will post 9.12 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on HUM. Royal Bank Of Canada lifted their target price on Humana from $246.00 to $415.00 and gave the stock a “sector perform” rating in a research report on Thursday, July 9th. Truist Financial upped their price target on shares of Humana from $320.00 to $415.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Needham & Company LLC initiated coverage on shares of Humana in a research note on Wednesday, May 20th. They issued a “buy” rating on the stock. Raymond James Financial lowered shares of Humana from an “outperform” rating to a “market perform” rating in a report on Thursday, July 30th. Finally, Bank of America upgraded shares of Humana from a “neutral” rating to a “buy” rating and set a $500.00 target price on the stock in a research note on Wednesday, July 29th. Fourteen analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $403.91.

View Our Latest Stock Analysis on HUM

Humana Profile

(Free Report)

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Featured Stories

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.